NLS Pharmaceutics AG
NLSP
$1.47
-$0.053-3.48%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.02M | -1.02M | -2.28M | -2.28M | -3.81M |
| Total Depreciation and Amortization | 2.90K | 2.90K | 2.90K | 2.90K | 2.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.70K | 49.70K | 89.70K | 89.70K | 22.50K |
| Change in Net Operating Assets | 200.10K | 200.10K | 993.20K | 993.20K | 132.70K |
| Cash from Operations | -765.20K | -765.20K | -1.19M | -1.19M | -3.65M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 816.90K | 816.90K | -- |
| Total Debt Repaid | -97.40K | -97.40K | -- | -- | -- |
| Issuance of Common Stock | 690.10K | 690.10K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 592.80K | 592.80K | 816.90K | 816.90K | -- |
| Foreign Exchange rate Adjustments | -- | -- | 200.00 | 200.00 | -200.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.50K | -172.50K | -376.90K | -376.90K | -3.65M |